Rationale for new treatments aimed at IgE immunomodulation
- 1 September 2004
- journal article
- review article
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 93 (3) , 212-217
- https://doi.org/10.1016/s1081-1206(10)61490-1
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Omalizumab treatment downregulates dendritic cell FcεRI expressionJournal of Allergy and Clinical Immunology, 2003
- Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitisPublished by Elsevier ,2003
- Omalizumab is effective in the long-term control of severe allergic asthmaAnnals of Allergy, Asthma & Immunology, 2003
- Peroxisome Proliferator–activated Receptors α and γ Down-regulate Allergic Inflammation and Eosinophil ActivationThe Journal of Experimental Medicine, 2003
- PPAR‐α and ‐γ but not ‐δ agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF‐κB‐independent effectBritish Journal of Pharmacology, 2003
- Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitisJournal of Allergy and Clinical Immunology, 2002
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Treatment of Allergic Asthma with Monoclonal Anti-IgE AntibodyNew England Journal of Medicine, 1999
- Down-regulation of Th2 cell-mediated murine peritoneal eosinophilia by antiallergic agentsLife Sciences, 1995
- Co‐crosslinking FcϵRII/CD23 and B cell surface immunoglobulin modulates B cell activationEuropean Journal of Immunology, 1992